Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 4/20 | 0.54 |
| ▸ | BACE1 | P56817 | 9/20 | 0.53 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.51 |
| ▸ | CTSD | P07339 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | KISS1R | Q969F8 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30799455 | 0.92 | BACE1 (0.61) | BACE1BACE2CTSD | |
| SCHEMBL30252365 | 0.91 | MME (0.51) | OPRD1BACE1OPRM1KISS1R | |
| SCHEMBL29697013 | 0.91 | MME (0.51) | OPRD1BACE1OPRM1KISS1R | |
| SCHEMBL31482984 | 0.90 | KISS1R (0.57) | OPRD1BACE1BACE2CTSDOPRM1 | |
| SCHEMBL30799878 | 0.90 | OPRD1 (0.58) | OPRD1BACE1BACE2CTSDOPRM1 | |
| SCHEMBL30799534 | 0.89 | BACE1 (0.62) | BACE1BACE2CTSD | |
| SCHEMBL29528212 | 0.89 | OPRD1 (0.57) | OPRD1OPRM1OPRK1KISS1R | |
| SCHEMBL30799630 | 0.89 | BACE1 (0.66) | BACE1BACE2CTSD | |
| SCHEMBL31406596 | 0.88 | KISS1R (0.53) | OPRD1BACE1CTSDOPRM1OPRK1 | |
| SCHEMBL29600830 | 0.88 | OPRD1 (0.54) | OPRD1BACE1CASP1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116985-A1 | STAPLED PEPTIDES AND METHODS THEREOF | PARABILIS MEDICINES, INC. | 2024-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116985-A1 | STAPLED PEPTIDES AND METHODS THEREOF | CTNNB1, APC, CTNNA1 | OPRD1 4412/4885BACE1 10/4885BACE2 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.